Level Four Advisory Services LLC Cuts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Level Four Advisory Services LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 2,117 shares of the medical research company’s stock after selling 86 shares during the period. Level Four Advisory Services LLC’s holdings in IQVIA were worth $421,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IQV. Hanson & Doremus Investment Management boosted its position in shares of IQVIA by 300.0% during the 1st quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 108 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA during the first quarter valued at $36,000. Financial Gravity Asset Management Inc. bought a new stake in shares of IQVIA in the 1st quarter worth about $1,989,000. Live Oak Investment Partners purchased a new stake in shares of IQVIA during the 4th quarter valued at about $41,000. Finally, Headlands Technologies LLC grew its position in IQVIA by 62.3% in the first quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after acquiring an additional 86 shares in the last quarter. Hedge funds and other institutional investors own 86.82% of the company’s stock.

IQVIA Trading Down 0.6 %

Shares of NYSE IQV opened at $211.71 on Monday. IQVIA Holdings Inc. has a twelve month low of $165.75 and a twelve month high of $241.86. The firm has a market cap of $38.77 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 2.15 and a beta of 1.37. The business has a fifty day simple moving average of $220.12 and a two-hundred day simple moving average of $208.08. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 2.16.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.13. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.70 billion. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. Analysts expect that IQVIA Holdings Inc. will post 9.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Barclays lifted their target price on IQVIA from $230.00 to $250.00 in a report on Tuesday, June 27th. HSBC initiated coverage on shares of IQVIA in a research report on Wednesday, September 6th. They set a “buy” rating and a $260.00 price objective on the stock. Truist Financial raised their target price on shares of IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Citigroup increased their price objective on shares of IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Morgan Stanley boosted their target price on IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $252.00.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.